Seattle-based Vedana Therapeutics has launched from stealth with a USD 46 million Series A financing round to advance a portfolio of antibody-based therapies targeting clinically validated pathways for migraine prevention. The round was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments.
Vedana's pipeline centers on pituitary adenylate cyclase-activating polypeptide (PACAP) biology. Its lead program is a next-generation anti-PACAP antibody, and its second program is a bispecific antibody targeting both PACAP and calcitonin gene-related peptide (CGRP). PACAP is a neuropeptide that, like CGRP, plays a documented role in migraine physiology. Vedana's antibodies are designed as long-acting, subcutaneously delivered agents intended for self-injection.
CGRP-targeted antibodies — including erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) — established the first generation of preventive migraine biologics and represented a meaningful clinical advance. However, the company and its investors contend that approximately two-thirds of patients remain inadequately controlled on existing therapies, creating a substantial opportunity for agents targeting complementary biology such as PACAP.